Liu Sui-Feng, Liu Song, Yu Qiao-Ting, Gao Tang-Gang, Zhang Yang, Cai Jia-Yi, Jia Chun-Wen, Zhao Ya-Nan, Gao Feng
Department of Cardiology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, 361000 Xiamen, Fujian, China.
Central Clinical Laboratory, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, 361000 Xiamen, Fujian, China.
Rev Cardiovasc Med. 2022 Oct 31;23(11):372. doi: 10.31083/j.rcm2311372. eCollection 2022 Nov.
The role of soluble interleukin-1 receptor type 2 (sIL-1R2) in acute myocardial infarction (AMI) remains undocumented. In the present study, we aimed to evaluate the possible associations of sIL-1R2 with left ventricular (LV) function, remodeling and future clinical events in the setting of AMI.
Circulating sIL-1R2 levels were quantified after percutaneous coronary intervention (PCI) on day 1 of hospital admission for 204 AMI patients, and upon enrollment of 204 healthy controls. Echocardiography was conducted in the acute phase and at 12-month follow-up. Adverse clinical events were registered after 12 months.
Circulating sIL-1R2 levels were significantly higher in AMI patients than in healthy controls (medians respectively 6652.81 pg/mL, 3799.13 pg/mL, 0.0001). AMI patients with sIL-1R2 levels less than the median had a larger proportion of worsened LV ejection fraction [a decrease in LV ejection fraction (LVEF) of more than 10% units] and reduced LVEF (a final LVEF 50%). After multivariate adjustment, sIL-1R2 levels less than the median were associated with an increased risk of worsened LVEF [odds ratio (OR): 3.7, 95% confidence interval (CI): 1.6-8.5, = 0.002] and reduced LVEF at 12 months (OR: 2.1, 95% CI: 1.1-4.3, = 0.035). Moreover, low sIL-1R2 levels were associated with an increased risk of having an adverse clinical event during the first 12 months after AMI [hazard ratio (HR): 2.5, 95% CI: 1.0-6.1, = 0.039].
Low levels of circulating sIL-1R2 were associated with impaired recovery of LV function and adverse clinical outcomes in AMI patients. These findings might contribute to understanding the important role of sIL-1R2 in postinfarction inflammation.
可溶性白细胞介素-1受体2型(sIL-1R2)在急性心肌梗死(AMI)中的作用仍未得到证实。在本研究中,我们旨在评估sIL-1R2与AMI患者左心室(LV)功能、重构及未来临床事件之间的可能关联。
对204例AMI患者入院第1天经皮冠状动脉介入治疗(PCI)后及204例健康对照者入组时的循环sIL-1R2水平进行定量分析。在急性期及12个月随访时进行超声心动图检查。记录12个月后的不良临床事件。
AMI患者的循环sIL-1R2水平显著高于健康对照者(中位数分别为6652.81 pg/mL、3799.13 pg/mL,P<0.0001)。sIL-1R2水平低于中位数的AMI患者左心室射血分数恶化(左心室射血分数降低超过10个百分点)及左心室射血分数降低(最终左心室射血分数≤50%)的比例更高。多因素调整后,sIL-1R2水平低于中位数与左心室射血分数恶化风险增加相关[比值比(OR):3.7,95%置信区间(CI):1.6-8.5,P=0.002],且与12个月时左心室射血分数降低相关(OR:2.1,95%CI:1.1-4.3,P=0.035)。此外,低sIL-1R2水平与AMI后前12个月发生不良临床事件的风险增加相关[风险比(HR):2.5,95%CI:1.0-6.1,P=0.039]。
循环sIL-1R2水平低与AMI患者左心室功能恢复受损及不良临床结局相关。这些发现可能有助于理解sIL-1R2在梗死后炎症中的重要作用。